FUSE-AI

We focus on Artificial Intelligence in diagnostic medicine and personalised medicine.

1. We develop intelligent tools for radiologists to detect lesions in MRI images faster and more safely for various indications - for prostate-, breast-, lung-cancer e.c..

2. We are involved in research projects with renowned university hospitals. We develop new AI Solutions for Robotic in Healthcare.

3. We are listed as a medical device manufacturer in Europe with the Federal Institute for Drugs and Medical Devices (BfArM). We are certified according to 13485.
We received the MDR II a certification for our product Prostate.Carcinoma.ai on 15.12.2023.
We will get the FDA approval in Q4

Challenge: The analysis of multiparametric MRIs (mpMRI) of the prostate is time consuming (>20 min), prone to error (false-positive-rate 14%) and the quality of findings depends to a large degree on the radiologist’s experience. Unnecessary treatment and the consequential complications as well as too-late recognition of tumours and reduced chances of a successful treatment process are the results of these false diagnoses.

Solution and customer benefit: Our software ProstateCarcinoma.ai is based on artificial neural networks. The software gives an independent second opinion on the detection of abnormalities, generates markers, conducts measurements.

• AI Solution for MRI prostate cancer diagnostic
• AI for Healtcare companies
• About us
• News

• Mr. Matthias Marianus Steffen
  CEO & Founder
  Großer Burstah 46-48

  Hamburg, 20457
  Phone: +49 171 269-0328
  Send an Email
  • LinkedIn
• Maximilian Waschka

Near by the Town hall